search
Back to results

Experimental Round Spermatid Injection (ROSI) to Treat Infertile Couples (ROSI)

Primary Purpose

Infertility, Male

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Round Spermatid Injection (ROSI)
Half ROSI-half Sperm Donor Fertilization
Sponsored by
Wake Forest University Health Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infertility, Male focused on measuring IVF, Fertility

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Males with no elongated spermatids or spermatozoa present but with round spermatids present on TESE (Testicular Sperm Extraction)
  • Male diagnosed with non-obstructive Azoospermia
  • Male partner ≥18
  • Female partner greater than 18 years of age and less than 38 years of age or Anti Mullerian Hormone (AMH) greater than 2 ng/ml.

Exclusion Criteria:

  • Males with obstructive azoospermia
  • Males with presence an adequate number of elongated spermatids or spermatozoa

Sites / Locations

  • Carolinas Fertility Institute (CFI)Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

ROSI only

Half ROSI-half Sperm Donor Fertilization

Arm Description

Option 1: injecting extracted round spermatids (less mature form of haploid germ cells than elongated spermatid or spermatozoon) from male partner into the harvested egg of a female partner

Option 2: Harvested eggs from the female partner will be separated in two groups, with one group being fertilized with round spermatids and the other group fertilized with donor sperm

Outcomes

Primary Outcome Measures

Fertility rate
Egg fertilization comparison between the groups undergoing the procedure with spermatids only vs spermatids and donor sperms.This fertilization process will be recorded by EmbryoScope under supervision of dedicated clinical embryologist.All the process will be followed and documented according to America Society of Reproductive Medicine (ASRM) guidelines. All the process will be followed and documented according to American Society for Reproductive Medicine (ASRM) guidelines.

Secondary Outcome Measures

Blastocyst formation
Blastocyst comparison between the groups undergoing the procedure with spermatids only vs spermatids and donor sperms.Embryo grow and blastocyst formation will be recorded by EmbryoScope under supervision of dedicated clinical embryologist.All the process will be followed and documented according to American Society for Reproductive Medicine (ASRM) guidelines.
Aneuploidy rate
Aneuploidy comparison and evaluation of abnormality between the groups undergoing the procedure with spermatids only vs spermatids and donor sperms. Aneuploidy will be tested using polymerase chain reaction amplification (PCR) based Preimplantation genetic diagnosis (PGD) and fluorescent in situ hybridization (FISH) analyses. All the process will be followed and documented according to American Society for Reproductive Medicine (ASRM) guidelines.
Chemical Pregnancy with Positive human chorionic gonadotropin (hCG)
Pregnancy Rate between the groups undergoing the procedure with spermatids only vs spermatids and donor sperms. Blood test to measure beta-hCG (chemical pregnancy) and follows by Ultrasound (clinical pregnancy). All the process will be followed and documented according to American Society for Reproductive Medicine (ASRM) guidelines.
Live Birth Rate
Live Birth comparison between the groups undergoing the procedure with spermatids only vs spermatids and donor sperms. Pregnancy will be followed as high risk and health of born children will be evaluated by a dedicated neonatologist/Pediatrician. All the process will be followed and documented according to American Society for Reproductive Medicine (ASRM) guidelines.

Full Information

First Posted
March 4, 2020
Last Updated
September 26, 2023
Sponsor
Wake Forest University Health Sciences
Collaborators
Carolinas Fertility Institute (CFI), Wake Forest Institute for Regenerative Medicine (WFIRM), Wake Forest Department of Urology
search

1. Study Identification

Unique Protocol Identification Number
NCT04298255
Brief Title
Experimental Round Spermatid Injection (ROSI) to Treat Infertile Couples
Acronym
ROSI
Official Title
Experimental Round Spermatid Injection (ROSI) to Treat Infertile Couples
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 24, 2020 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Wake Forest University Health Sciences
Collaborators
Carolinas Fertility Institute (CFI), Wake Forest Institute for Regenerative Medicine (WFIRM), Wake Forest Department of Urology

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this research study is to evaluate if special types of cells called round spermatids can be gathered from men with non-obstructive azoospermia and used (in absence of elongated spermatids and spermatozoa) to reliably and effectively create pregnancy with a procedure called Round Spermatid Injection (ROSI). This process is similar to In Vitro Fertilization, or 'IVF'. In addition, this study wants to test the safety of ROSI and see what effects (good and bad) it has on embryo created from this method.
Detailed Description
Azoospermia is defined as the absence of sperm in the ejaculate. Around 1% of general population suffers from azoospermia. Men who were rendered infertile due to a non-obstructive azoospermia, who have been subjected to Testicular Sperm Extraction (TESE) surgery and found to be lacking elongated spermatids or spermatozoa, are commonly advised to consider utilizing a sperm donor or apply for adoption. It is reported that ~30% of men with non-obstructive azoospermia lack elongated spermatids and spermatozoa but may still produce round spermatids (less mature form of haploid germ cells) in their testicles. Round Spermatid Injection (ROSI) technology to fertilize oocytes is not a brand-new technology, however, it is plagued with notoriously low efficiency. Despite this limitation, it has been reported that most of these patients still desire to have the ROSI procedure instead of applying directly for other options, i.e. sperm donation or adoption. High failure rate of traditional ROSI has been attributed to a few potential causes: Incorrect selection of round spermatids (to distinguish from diploid spermatogonia cells) Using round spermatids that were already in the process of degeneration Incomplete imprinting in the round spermatid Incomplete activation of oocytes Recently Tanaka and colleagues in Japan established a new ROSI method and reported over 90 babies born via this method1. They described a new method of round spermatid selection and oocyte activation using NEPA21 super electroporator (10 minutes prior to round spermatid injection). Babies born from this new ROSI method in Japan have been evaluated for developmental and cognitive differences for 2 years1. Babies conceived with ROSI were found to have a shorter gestation times, and lower body weight at 12 and 18 months when compared to their naturally conceived counterparts, but also showed an increased birth weight and showed no body weight differences at 24 months of age. No diseases resulting from genetic anomalies have been reported thus far, but the relatively small sample sizes present in the literature needs to be tested in larger cohorts. Therefore, this effective ROSI method should still be considered as an "experimental fertility treatment".

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility, Male
Keywords
IVF, Fertility

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Infertile Male with round spermatid (but not elongated spermatids and spermatozoa) in their testes. Couples can choose either option 1 or 2.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ROSI only
Arm Type
Experimental
Arm Description
Option 1: injecting extracted round spermatids (less mature form of haploid germ cells than elongated spermatid or spermatozoon) from male partner into the harvested egg of a female partner
Arm Title
Half ROSI-half Sperm Donor Fertilization
Arm Type
Experimental
Arm Description
Option 2: Harvested eggs from the female partner will be separated in two groups, with one group being fertilized with round spermatids and the other group fertilized with donor sperm
Intervention Type
Other
Intervention Name(s)
Round Spermatid Injection (ROSI)
Intervention Description
In Vitro Fertilization using Round Spermatid Injection (ROSI)
Intervention Type
Other
Intervention Name(s)
Half ROSI-half Sperm Donor Fertilization
Intervention Description
Half ROSI-half Sperm Donor Fertilization
Primary Outcome Measure Information:
Title
Fertility rate
Description
Egg fertilization comparison between the groups undergoing the procedure with spermatids only vs spermatids and donor sperms.This fertilization process will be recorded by EmbryoScope under supervision of dedicated clinical embryologist.All the process will be followed and documented according to America Society of Reproductive Medicine (ASRM) guidelines. All the process will be followed and documented according to American Society for Reproductive Medicine (ASRM) guidelines.
Time Frame
Day 1 after round spermatid injection
Secondary Outcome Measure Information:
Title
Blastocyst formation
Description
Blastocyst comparison between the groups undergoing the procedure with spermatids only vs spermatids and donor sperms.Embryo grow and blastocyst formation will be recorded by EmbryoScope under supervision of dedicated clinical embryologist.All the process will be followed and documented according to American Society for Reproductive Medicine (ASRM) guidelines.
Time Frame
Day 3 to 5 after round spermatid injection
Title
Aneuploidy rate
Description
Aneuploidy comparison and evaluation of abnormality between the groups undergoing the procedure with spermatids only vs spermatids and donor sperms. Aneuploidy will be tested using polymerase chain reaction amplification (PCR) based Preimplantation genetic diagnosis (PGD) and fluorescent in situ hybridization (FISH) analyses. All the process will be followed and documented according to American Society for Reproductive Medicine (ASRM) guidelines.
Time Frame
Day 3 to 5 after round spermatid injection
Title
Chemical Pregnancy with Positive human chorionic gonadotropin (hCG)
Description
Pregnancy Rate between the groups undergoing the procedure with spermatids only vs spermatids and donor sperms. Blood test to measure beta-hCG (chemical pregnancy) and follows by Ultrasound (clinical pregnancy). All the process will be followed and documented according to American Society for Reproductive Medicine (ASRM) guidelines.
Time Frame
Post Fertilization 4 Weeks and onwards
Title
Live Birth Rate
Description
Live Birth comparison between the groups undergoing the procedure with spermatids only vs spermatids and donor sperms. Pregnancy will be followed as high risk and health of born children will be evaluated by a dedicated neonatologist/Pediatrician. All the process will be followed and documented according to American Society for Reproductive Medicine (ASRM) guidelines.
Time Frame
Post Pregnancy Full Term Average 39 to 40 weeks

10. Eligibility

Sex
Male
Gender Based
Yes
Gender Eligibility Description
Males with absence of elongated spermatids or spermatozoa, but having round spermatids present on TESE (Testicular Sperm Extraction) Male diagnosed with non-obstructive Azoospermia Female partner 18≤ X≤38 years of age (because of expected lower quality of oocytes in older females)
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males with no elongated spermatids or spermatozoa present but with round spermatids present on TESE (Testicular Sperm Extraction) Male diagnosed with non-obstructive Azoospermia Male partner ≥18 Female partner greater than 18 years of age and less than 38 years of age or Anti Mullerian Hormone (AMH) greater than 2 ng/ml. Exclusion Criteria: Males with obstructive azoospermia Males with presence an adequate number of elongated spermatids or spermatozoa
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sachin Vyas, MSc, PhD
Phone
(336) 713-4098
Email
svyas@wakehealth.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hooman Sadri, MD, PhD
Organizational Affiliation
Wake Forest Institute for Regenerative Medicine (WFIRM)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Hooman Sadri, MD, PhD
Organizational Affiliation
Wake Forest University Health Sciences
Official's Role
Study Director
Facility Information:
Facility Name
Carolinas Fertility Institute (CFI)
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tamer Yalcinkaya, MD
First Name & Middle Initial & Last Name & Degree
Hooman Sadri, MD, PhD
First Name & Middle Initial & Last Name & Degree
Banafsheh Nikmehr, PhD
First Name & Middle Initial & Last Name & Degree
Anuradha Devineni, MD, MS

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Individual Participant Data will be available to research teams of Carolinas Fertility Institute and Wake Forest University. It will not be shared with others. Data will be available in the form of electronic charts at the Carolinas Fertility Institute, and limited hard copies at the Wake Forest University Urology Department.
Citations:
PubMed Identifier
30098696
Citation
Tanaka A, Suzuki K, Nagayoshi M, Tanaka A, Takemoto Y, Watanabe S, Takeda S, Irahara M, Kuji N, Yamagata Z, Yanagimachi R. Ninety babies born after round spermatid injection into oocytes: survey of their development from fertilization to 2 years of age. Fertil Steril. 2018 Aug;110(3):443-451. doi: 10.1016/j.fertnstert.2018.04.033.
Results Reference
background
PubMed Identifier
26575628
Citation
Tanaka A, Nagayoshi M, Takemoto Y, Tanaka I, Kusunoki H, Watanabe S, Kuroda K, Takeda S, Ito M, Yanagimachi R. Fourteen babies born after round spermatid injection into human oocytes. Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14629-34. doi: 10.1073/pnas.1517466112. Epub 2015 Nov 2. Erratum In: Proc Natl Acad Sci U S A. 2016 May 17;113(20):E2872.
Results Reference
background
PubMed Identifier
34618410
Citation
Bradshaw AW, Nikmehr B, Halicigil C, Stogner-Underwood K, Sadri-Ardekani H. Optimum identification of round spermatid in men with non-obstructive azoospermia: A commentary. Andrology. 2021 Nov;9(6):1817-1818. doi: 10.1111/andr.13113. Epub 2021 Oct 14. No abstract available.
Results Reference
background

Learn more about this trial

Experimental Round Spermatid Injection (ROSI) to Treat Infertile Couples

We'll reach out to this number within 24 hrs